Jennifer Richer
Concepts (456)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 16 | 2025 | 206 | 6.310 |
Why?
| | Receptors, Androgen | 14 | 2025 | 155 | 5.660 |
Why?
| | Breast Neoplasms | 47 | 2026 | 2340 | 4.420 |
Why?
| | MicroRNAs | 17 | 2018 | 703 | 3.550 |
Why?
| | Androgen Receptor Antagonists | 8 | 2021 | 35 | 2.310 |
Why?
| | Anoikis | 7 | 2021 | 31 | 2.120 |
Why?
| | Receptors, Estrogen | 15 | 2025 | 426 | 2.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 35 | 2025 | 1491 | 2.030 |
Why?
| | Cell Line, Tumor | 40 | 2026 | 3626 | 2.000 |
Why?
| | Phenylthiohydantoin | 7 | 2025 | 44 | 1.870 |
Why?
| | Tryptophan | 4 | 2024 | 182 | 1.850 |
Why?
| | Estrogen Receptor alpha | 6 | 2022 | 149 | 1.750 |
Why?
| | Receptors, Progesterone | 24 | 2016 | 345 | 1.750 |
Why?
| | Tryptophan Oxygenase | 5 | 2024 | 34 | 1.590 |
Why?
| | Ovarian Neoplasms | 6 | 2024 | 591 | 1.090 |
Why?
| | Palmitates | 1 | 2025 | 21 | 0.940 |
Why?
| | Progesterone | 16 | 2014 | 258 | 0.940 |
Why?
| | Neoplasm Invasiveness | 4 | 2024 | 523 | 0.940 |
Why?
| | Benzamides | 8 | 2026 | 224 | 0.930 |
Why?
| | Tamoxifen | 10 | 2016 | 204 | 0.900 |
Why?
| | Progestins | 6 | 2014 | 85 | 0.900 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 880 | 0.880 |
Why?
| | Oxidative Phosphorylation | 1 | 2025 | 207 | 0.860 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 58 | 0.850 |
Why?
| | Ribonuclease III | 2 | 2016 | 44 | 0.810 |
Why?
| | Neoplastic Stem Cells | 3 | 2017 | 414 | 0.780 |
Why?
| | DEAD-box RNA Helicases | 2 | 2016 | 90 | 0.770 |
Why?
| | Epithelial Cells | 3 | 2022 | 1136 | 0.770 |
Why?
| | Wound Healing | 1 | 2026 | 365 | 0.770 |
Why?
| | Epithelial-Mesenchymal Transition | 5 | 2018 | 219 | 0.760 |
Why?
| | Adipokines | 2 | 2024 | 58 | 0.750 |
Why?
| | Biomarkers, Tumor | 7 | 2021 | 1300 | 0.740 |
Why?
| | Cell Proliferation | 14 | 2021 | 2551 | 0.720 |
Why?
| | Kallikreins | 1 | 2021 | 26 | 0.710 |
Why?
| | Nitriles | 7 | 2025 | 193 | 0.710 |
Why?
| | Gene Expression Profiling | 11 | 2018 | 1801 | 0.680 |
Why?
| | Prostate-Specific Antigen | 1 | 2021 | 166 | 0.670 |
Why?
| | Female | 66 | 2026 | 78073 | 0.640 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 156 | 0.640 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 176 | 0.640 |
Why?
| | Endometrial Neoplasms | 6 | 2011 | 200 | 0.640 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2023 | 1109 | 0.640 |
Why?
| | Immunohistochemistry | 8 | 2017 | 1740 | 0.640 |
Why?
| | Trophoblasts | 1 | 2022 | 218 | 0.620 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2021 | 175 | 0.620 |
Why?
| | Pulmonary Alveoli | 1 | 2022 | 393 | 0.620 |
Why?
| | Transcription Factors | 13 | 2023 | 1762 | 0.620 |
Why?
| | Androgen Antagonists | 3 | 2017 | 92 | 0.610 |
Why?
| | Cell Movement | 9 | 2020 | 974 | 0.610 |
Why?
| | Mammary Glands, Animal | 4 | 2022 | 129 | 0.610 |
Why?
| | Humans | 94 | 2026 | 144746 | 0.600 |
Why?
| | Homeodomain Proteins | 5 | 2014 | 526 | 0.590 |
Why?
| | Alternative Splicing | 2 | 2018 | 245 | 0.590 |
Why?
| | Repressor Proteins | 6 | 2018 | 438 | 0.580 |
Why?
| | Mice | 25 | 2026 | 18497 | 0.580 |
Why?
| | Lung Neoplasms | 2 | 2026 | 2603 | 0.570 |
Why?
| | Cell Cycle | 4 | 2021 | 650 | 0.560 |
Why?
| | Up-Regulation | 7 | 2020 | 863 | 0.560 |
Why?
| | Animals | 40 | 2026 | 38223 | 0.560 |
Why?
| | Tumor Microenvironment | 6 | 2026 | 737 | 0.560 |
Why?
| | RNA Splicing Factors | 1 | 2018 | 63 | 0.560 |
Why?
| | Mammary Neoplasms, Experimental | 3 | 2017 | 68 | 0.550 |
Why?
| | Carcinoma, Endometrioid | 2 | 2008 | 50 | 0.500 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2021 | 949 | 0.500 |
Why?
| | Gonadal Steroid Hormones | 1 | 2018 | 144 | 0.490 |
Why?
| | Lactation | 2 | 2022 | 193 | 0.490 |
Why?
| | Lipogenesis | 1 | 2016 | 64 | 0.480 |
Why?
| | MCF-7 Cells | 4 | 2025 | 130 | 0.480 |
Why?
| | Paclitaxel | 3 | 2017 | 237 | 0.480 |
Why?
| | Antibody Specificity | 1 | 2016 | 185 | 0.480 |
Why?
| | Receptor, trkB | 2 | 2012 | 36 | 0.460 |
Why?
| | Signal Transduction | 19 | 2025 | 5242 | 0.460 |
Why?
| | Antineoplastic Agents | 6 | 2018 | 2209 | 0.460 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2015 | 57 | 0.450 |
Why?
| | Apoptosis | 11 | 2020 | 2514 | 0.440 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.430 |
Why?
| | Kynurenine | 4 | 2024 | 115 | 0.420 |
Why?
| | RNA Interference | 3 | 2015 | 475 | 0.420 |
Why?
| | Antibodies | 1 | 2016 | 403 | 0.410 |
Why?
| | Receptors, Steroid | 2 | 2010 | 46 | 0.410 |
Why?
| | Metformin | 2 | 2014 | 332 | 0.410 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 445 | 0.400 |
Why?
| | Carnitine O-Palmitoyltransferase | 2 | 2025 | 48 | 0.390 |
Why?
| | Gene Expression Regulation | 8 | 2016 | 2621 | 0.380 |
Why?
| | Chromatin | 1 | 2016 | 554 | 0.370 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 929 | 0.360 |
Why?
| | Mutation | 8 | 2025 | 4080 | 0.360 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 77 | 0.360 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 56 | 0.350 |
Why?
| | Neoadjuvant Therapy | 2 | 2020 | 442 | 0.350 |
Why?
| | Cystadenocarcinoma, Serous | 2 | 2024 | 85 | 0.350 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1842 | 0.350 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2020 | 173 | 0.350 |
Why?
| | Neoplasm Metastasis | 4 | 2026 | 689 | 0.350 |
Why?
| | Disease Progression | 6 | 2018 | 2889 | 0.340 |
Why?
| | Endometrium | 2 | 2008 | 62 | 0.340 |
Why?
| | NF-kappa B | 3 | 2025 | 687 | 0.330 |
Why?
| | Transcriptional Activation | 5 | 2017 | 380 | 0.320 |
Why?
| | Mice, SCID | 4 | 2020 | 374 | 0.320 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 341 | 0.310 |
Why?
| | Tubulin Modulators | 1 | 2009 | 11 | 0.300 |
Why?
| | Cells | 1 | 2009 | 25 | 0.300 |
Why?
| | Estradiol | 6 | 2016 | 528 | 0.300 |
Why?
| | 3' Untranslated Regions | 4 | 2014 | 152 | 0.290 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 4 | 2011 | 24 | 0.290 |
Why?
| | Uterine Neoplasms | 2 | 2008 | 96 | 0.290 |
Why?
| | Cadherins | 4 | 2012 | 204 | 0.290 |
Why?
| | Killer Cells, Natural | 2 | 2025 | 475 | 0.290 |
Why?
| | Dirofilaria immitis | 3 | 2010 | 3 | 0.280 |
Why?
| | Neoplasms | 5 | 2022 | 2823 | 0.270 |
Why?
| | Mice, Nude | 5 | 2017 | 709 | 0.270 |
Why?
| | Feedback, Physiological | 2 | 2021 | 81 | 0.260 |
Why?
| | Trastuzumab | 2 | 2017 | 104 | 0.260 |
Why?
| | Cell Nucleus | 5 | 2017 | 617 | 0.250 |
Why?
| | Transfection | 5 | 2012 | 950 | 0.250 |
Why?
| | Microtubules | 1 | 2009 | 285 | 0.250 |
Why?
| | Epidermal Growth Factor | 4 | 2005 | 174 | 0.240 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2026 | 15 | 0.240 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2026 | 12 | 0.240 |
Why?
| | Genetic Diseases, Inborn | 2 | 2017 | 46 | 0.240 |
Why?
| | Cyclopropanes | 1 | 2026 | 81 | 0.240 |
Why?
| | Aminopyridines | 1 | 2026 | 120 | 0.230 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2026 | 146 | 0.230 |
Why?
| | Fibrillin-1 | 1 | 2024 | 6 | 0.220 |
Why?
| | Alveolar Epithelial Cells | 1 | 2026 | 121 | 0.220 |
Why?
| | Anilides | 2 | 2016 | 80 | 0.220 |
Why?
| | Mice, Inbred NOD | 3 | 2020 | 611 | 0.220 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 116 | 0.220 |
Why?
| | Marfan Syndrome | 1 | 2024 | 45 | 0.220 |
Why?
| | Down-Regulation | 6 | 2016 | 647 | 0.220 |
Why?
| | Gene Expression | 4 | 2020 | 1505 | 0.210 |
Why?
| | Cell Differentiation | 1 | 2012 | 2041 | 0.210 |
Why?
| | Microarray Analysis | 2 | 2016 | 118 | 0.210 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 9 | 0.200 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 763 | 0.200 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 441 | 0.200 |
Why?
| | Tumor Cells, Cultured | 11 | 2020 | 974 | 0.180 |
Why?
| | Milk Proteins | 2 | 1999 | 35 | 0.180 |
Why?
| | Mammary Glands, Human | 2 | 2014 | 67 | 0.180 |
Why?
| | Genetic Variation | 2 | 2024 | 1012 | 0.180 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 98 | 0.180 |
Why?
| | Epithelium | 1 | 2022 | 314 | 0.170 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 685 | 0.170 |
Why?
| | Estrogens | 3 | 2020 | 372 | 0.170 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2188 | 0.170 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2022 | 80 | 0.170 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 101 | 0.170 |
Why?
| | Promoter Regions, Genetic | 6 | 2014 | 1264 | 0.170 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 444 | 0.160 |
Why?
| | DNA-Binding Proteins | 6 | 2018 | 1526 | 0.160 |
Why?
| | Semaphorins | 1 | 2020 | 37 | 0.160 |
Why?
| | Epoxy Compounds | 1 | 2020 | 32 | 0.160 |
Why?
| | Androgens | 1 | 2021 | 194 | 0.160 |
Why?
| | Immune Tolerance | 1 | 2022 | 381 | 0.160 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 336 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 68 | 0.160 |
Why?
| | Respiratory Mucosa | 1 | 2022 | 327 | 0.150 |
Why?
| | STAT5 Transcription Factor | 3 | 2014 | 56 | 0.150 |
Why?
| | Transcription, Genetic | 9 | 2012 | 1514 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 395 | 0.150 |
Why?
| | RNA, Messenger | 7 | 2011 | 2856 | 0.150 |
Why?
| | Mitochondria | 1 | 2025 | 990 | 0.150 |
Why?
| | Pregnancy | 3 | 2022 | 7211 | 0.140 |
Why?
| | Prolactin | 1 | 1998 | 92 | 0.140 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 640 | 0.140 |
Why?
| | Gene Amplification | 1 | 2018 | 111 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 706 | 0.140 |
Why?
| | Immunoblotting | 3 | 2010 | 313 | 0.140 |
Why?
| | Endometrial Hyperplasia | 2 | 2008 | 7 | 0.130 |
Why?
| | Binding Sites | 5 | 2016 | 1330 | 0.130 |
Why?
| | Antigens, CD | 1 | 2020 | 553 | 0.130 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2017 | 45 | 0.130 |
Why?
| | Cluster Analysis | 4 | 2008 | 529 | 0.130 |
Why?
| | Dihydrotestosterone | 1 | 2017 | 44 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 269 | 0.130 |
Why?
| | Histone Acetyltransferases | 3 | 2006 | 63 | 0.130 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 253 | 0.130 |
Why?
| | Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.130 |
Why?
| | Heterografts | 1 | 2017 | 138 | 0.130 |
Why?
| | Fatty Acids | 1 | 2020 | 454 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 111 | 0.120 |
Why?
| | Cyclohexanes | 1 | 2016 | 23 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 220 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 2 | 2014 | 331 | 0.120 |
Why?
| | Enzyme Inhibitors | 3 | 2024 | 839 | 0.120 |
Why?
| | Trans-Activators | 4 | 2006 | 403 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 233 | 0.120 |
Why?
| | Hyaluronan Receptors | 2 | 2014 | 104 | 0.120 |
Why?
| | Ovary | 1 | 2017 | 229 | 0.120 |
Why?
| | Placenta | 1 | 2022 | 783 | 0.120 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 197 | 0.110 |
Why?
| | Genes | 1 | 2015 | 229 | 0.110 |
Why?
| | Genetic Association Studies | 1 | 2017 | 380 | 0.110 |
Why?
| | Phosphoproteins | 2 | 2008 | 342 | 0.110 |
Why?
| | Hormones | 1 | 2015 | 139 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 825 | 0.110 |
Why?
| | Exome | 1 | 2015 | 240 | 0.100 |
Why?
| | Tosyl Compounds | 1 | 2014 | 16 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 378 | 0.100 |
Why?
| | Genes, Reporter | 2 | 2012 | 273 | 0.100 |
Why?
| | Ligands | 6 | 2023 | 672 | 0.100 |
Why?
| | Protein Transport | 1 | 2015 | 448 | 0.100 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 102 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2015 | 165 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2016 | 747 | 0.100 |
Why?
| | In Situ Hybridization | 2 | 2010 | 321 | 0.100 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 1993 | 50 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2024 | 2444 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2016 | 4185 | 0.100 |
Why?
| | Cellular Reprogramming | 1 | 2014 | 103 | 0.100 |
Why?
| | Neurotrophin 3 | 1 | 2012 | 10 | 0.100 |
Why?
| | Cell Adhesion | 2 | 2012 | 457 | 0.100 |
Why?
| | Autocrine Communication | 1 | 2012 | 40 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2021 | 4553 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1048 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2015 | 374 | 0.090 |
Why?
| | Ketones | 1 | 1993 | 52 | 0.090 |
Why?
| | Metalloendopeptidases | 1 | 1992 | 62 | 0.090 |
Why?
| | Aromatase Inhibitors | 2 | 2014 | 58 | 0.090 |
Why?
| | Cysteine Endopeptidases | 1 | 1992 | 75 | 0.090 |
Why?
| | Family | 1 | 2017 | 687 | 0.090 |
Why?
| | Middle Aged | 7 | 2024 | 35639 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2012 | 136 | 0.090 |
Why?
| | Disease-Free Survival | 1 | 2014 | 725 | 0.090 |
Why?
| | Gene Silencing | 2 | 2014 | 201 | 0.090 |
Why?
| | Nuclear Proteins | 5 | 2000 | 760 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2023 | 752 | 0.090 |
Why?
| | Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 6 | 0.090 |
Why?
| | Receptors, Leptin | 1 | 2011 | 25 | 0.090 |
Why?
| | Tumor Burden | 1 | 2012 | 319 | 0.090 |
Why?
| | Tubulin | 1 | 2012 | 146 | 0.090 |
Why?
| | Tissue Array Analysis | 2 | 2008 | 51 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2016 | 6054 | 0.080 |
Why?
| | GTPase-Activating Proteins | 1 | 2011 | 85 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2098 | 0.080 |
Why?
| | Fibronectins | 1 | 2011 | 138 | 0.080 |
Why?
| | Protein Biosynthesis | 2 | 2012 | 454 | 0.080 |
Why?
| | Microfilament Proteins | 1 | 2011 | 135 | 0.080 |
Why?
| | Cell Transdifferentiation | 1 | 2010 | 31 | 0.080 |
Why?
| | HeLa Cells | 5 | 2006 | 649 | 0.080 |
Why?
| | Retinoid X Receptors | 1 | 2010 | 38 | 0.080 |
Why?
| | Cyclins | 3 | 1999 | 101 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2010 | 346 | 0.080 |
Why?
| | DNA, Complementary | 4 | 2008 | 277 | 0.080 |
Why?
| | Breast | 2 | 2022 | 158 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 994 | 0.080 |
Why?
| | Protein Isoforms | 4 | 2006 | 404 | 0.080 |
Why?
| | Lung | 1 | 2022 | 4130 | 0.070 |
Why?
| | Cell Line, Transformed | 1 | 2009 | 146 | 0.070 |
Why?
| | Prognosis | 3 | 2024 | 4207 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2905 | 0.070 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2023 | 209 | 0.070 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.070 |
Why?
| | S100 Proteins | 1 | 2008 | 36 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1045 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3403 | 0.070 |
Why?
| | Leiomyoma | 1 | 2008 | 58 | 0.070 |
Why?
| | Drug Interactions | 1 | 2009 | 407 | 0.070 |
Why?
| | Aged | 5 | 2024 | 25564 | 0.070 |
Why?
| | Glycoproteins | 2 | 2024 | 356 | 0.060 |
Why?
| | Hysterectomy | 1 | 2008 | 139 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2024 | 792 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 64 | 0.060 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2944 | 0.060 |
Why?
| | Stem Cells | 1 | 2010 | 620 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 2025 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 29 | 0.060 |
Why?
| | Canada | 2 | 2017 | 432 | 0.050 |
Why?
| | Precancerous Conditions | 1 | 2006 | 167 | 0.050 |
Why?
| | Thromboplastin | 1 | 2004 | 73 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 3 | 1999 | 127 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2008 | 1422 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2024 | 57 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3076 | 0.050 |
Why?
| | Protein Binding | 4 | 2010 | 2277 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1413 | 0.050 |
Why?
| | Ovariectomy | 2 | 2017 | 160 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 313 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 475 | 0.050 |
Why?
| | Postmenopause | 3 | 2017 | 379 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2025 | 227 | 0.050 |
Why?
| | Amino Acid Sequence | 4 | 2010 | 2168 | 0.050 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 30 | 0.050 |
Why?
| | Genome, Human | 1 | 2024 | 429 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2005 | 617 | 0.050 |
Why?
| | Immune Evasion | 1 | 2022 | 66 | 0.040 |
Why?
| | Larva | 2 | 1993 | 240 | 0.040 |
Why?
| | Biology | 1 | 2022 | 91 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 243 | 0.040 |
Why?
| | Promegestone | 4 | 2005 | 33 | 0.040 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 167 | 0.040 |
Why?
| | Mifepristone | 2 | 2000 | 63 | 0.040 |
Why?
| | Drug Resistance | 2 | 2000 | 153 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 562 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 580 | 0.040 |
Why?
| | Adult | 4 | 2016 | 40358 | 0.040 |
Why?
| | Fibroblasts | 1 | 2006 | 1047 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 290 | 0.040 |
Why?
| | Zinc | 1 | 2024 | 300 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2020 | 80 | 0.040 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 16 | 0.040 |
Why?
| | Exons | 2 | 1999 | 360 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2015 | 11498 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 99 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1999 | 55 | 0.040 |
Why?
| | Postpartum Period | 1 | 2022 | 358 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 829 | 0.040 |
Why?
| | Young Adult | 1 | 2016 | 14021 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2006 | 926 | 0.040 |
Why?
| | Receptor Cross-Talk | 1 | 1998 | 21 | 0.040 |
Why?
| | Immunological Synapses | 1 | 2018 | 17 | 0.040 |
Why?
| | p300-CBP Transcription Factors | 1 | 2018 | 27 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 1998 | 71 | 0.040 |
Why?
| | DNA Helicases | 1 | 2000 | 145 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2008 | 8103 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 142 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1998 | 194 | 0.030 |
Why?
| | Oxygenases | 1 | 1997 | 13 | 0.030 |
Why?
| | Drug Synergism | 1 | 1998 | 370 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 46 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 413 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1263 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 376 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 1998 | 302 | 0.030 |
Why?
| | Consanguinity | 1 | 2017 | 50 | 0.030 |
Why?
| | Male | 3 | 2021 | 72210 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2005 | 1315 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 1998 | 210 | 0.030 |
Why?
| | Ribosomal Proteins | 1 | 1997 | 93 | 0.030 |
Why?
| | Carcinogens | 1 | 1997 | 126 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 273 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 1999 | 450 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 165 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2010 | 367 | 0.030 |
Why?
| | Siblings | 1 | 2017 | 217 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1095 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2000 | 411 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1509 | 0.030 |
Why?
| | Pedigree | 1 | 2017 | 517 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 454 | 0.030 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 15 | 0.030 |
Why?
| | Histones | 2 | 2014 | 676 | 0.030 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 28 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1273 | 0.030 |
Why?
| | Base Sequence | 3 | 2008 | 2201 | 0.030 |
Why?
| | Keratin-5 | 1 | 2014 | 48 | 0.030 |
Why?
| | Nuclear Receptor Coactivator 1 | 2 | 2006 | 10 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 740 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 475 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 424 | 0.020 |
Why?
| | DNA Primers | 2 | 2008 | 519 | 0.020 |
Why?
| | Dipeptides | 1 | 1993 | 56 | 0.020 |
Why?
| | Chromatography | 1 | 1992 | 22 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2017 | 654 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1993 | 415 | 0.020 |
Why?
| | Elastin | 1 | 1992 | 84 | 0.020 |
Why?
| | Hydrolysis | 1 | 1992 | 199 | 0.020 |
Why?
| | Protease Inhibitors | 1 | 1992 | 104 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 554 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1878 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5345 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2010 | 201 | 0.020 |
Why?
| | Oligopeptides | 1 | 1992 | 267 | 0.020 |
Why?
| | Cell Size | 1 | 2010 | 91 | 0.020 |
Why?
| | COS Cells | 2 | 2003 | 179 | 0.020 |
Why?
| | Cell Dedifferentiation | 1 | 2010 | 32 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2010 | 26 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 88 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2010 | 150 | 0.020 |
Why?
| | Collagen | 1 | 1992 | 468 | 0.020 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 14 | 0.020 |
Why?
| | DNA Methylation | 1 | 2014 | 670 | 0.020 |
Why?
| | Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5615 | 0.020 |
Why?
| | Phosphorylation | 2 | 2005 | 1787 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3236 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 84 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2061 | 0.020 |
Why?
| | Cell Division | 2 | 2000 | 806 | 0.020 |
Why?
| | Myometrium | 1 | 2008 | 39 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 1992 | 565 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 74 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 162 | 0.020 |
Why?
| | Trypan Blue | 1 | 2006 | 6 | 0.020 |
Why?
| | United States | 1 | 2025 | 15694 | 0.020 |
Why?
| | Comet Assay | 1 | 2006 | 16 | 0.020 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2006 | 5 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 57 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2006 | 75 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2006 | 83 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2006 | 153 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2006 | 104 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 2 | 2000 | 681 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4276 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2006 | 226 | 0.010 |
Why?
| | Androstenes | 1 | 2005 | 17 | 0.010 |
Why?
| | Caspase 3 | 1 | 2006 | 252 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2006 | 160 | 0.010 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2005 | 37 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2005 | 36 | 0.010 |
Why?
| | Desogestrel | 1 | 2005 | 46 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 368 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2006 | 176 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2005 | 147 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 111 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2006 | 318 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 253 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 488 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 863 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 326 | 0.010 |
Why?
| | DNA Damage | 1 | 2006 | 449 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 643 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 398 | 0.010 |
Why?
| | Progesterone Congeners | 1 | 2002 | 15 | 0.010 |
Why?
| | Mutagenesis | 1 | 2003 | 186 | 0.010 |
Why?
| | Uterus | 1 | 2003 | 227 | 0.010 |
Why?
| | Dimerization | 1 | 2002 | 197 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11876 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1137 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 371 | 0.010 |
Why?
| | Ku Autoantigen | 1 | 2000 | 11 | 0.010 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 16 | 0.010 |
Why?
| | Glutathione Transferase | 1 | 2000 | 99 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1372 | 0.010 |
Why?
| | Culture Techniques | 1 | 1999 | 74 | 0.010 |
Why?
| | Methionine | 1 | 2000 | 160 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1478 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2003 | 706 | 0.010 |
Why?
| | Growth Substances | 1 | 1999 | 140 | 0.010 |
Why?
| | Estrogen Receptor beta | 1 | 1999 | 43 | 0.010 |
Why?
| | Cricetinae | 1 | 1999 | 301 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1998 | 40 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 1998 | 56 | 0.010 |
Why?
| | Premenopause | 1 | 1999 | 121 | 0.010 |
Why?
| | RNA | 1 | 2005 | 939 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2017 | 16942 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 155 | 0.010 |
Why?
| | Sp1 Transcription Factor | 1 | 1998 | 25 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1999 | 517 | 0.010 |
Why?
| | Estrogen Antagonists | 1 | 1998 | 46 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 151 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 183 | 0.010 |
Why?
| | Isomerism | 1 | 1997 | 54 | 0.010 |
Why?
| | Gene Deletion | 1 | 1999 | 394 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 273 | 0.010 |
Why?
| | Leucine Zippers | 1 | 1997 | 16 | 0.010 |
Why?
| | Yeasts | 1 | 1997 | 52 | 0.010 |
Why?
| | Autoantigens | 1 | 2000 | 427 | 0.010 |
Why?
| | Blotting, Western | 1 | 1998 | 1223 | 0.010 |
Why?
| | Child | 1 | 2015 | 22928 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1063 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 7074 | 0.010 |
Why?
| | Cell Line | 1 | 1998 | 2900 | 0.010 |
Why?
| | Cytokines | 1 | 1999 | 2102 | 0.010 |
Why?
| | Models, Biological | 1 | 1998 | 1838 | 0.010 |
Why?
|
|
Richer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|